Tirzepatide is a groundbreaking pharmaceutical agent for individuals facing type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, promoting synergistic effects on blood sugar control. By enhancing insulin secretion while simultaneously reducing gl